08/27/2026
As GLP-1 use continues to evolve and clinicians increasingly push beyond the boundaries of traditional evidence-based practice, one topic drawing a lot of attention lately is dosing frequency.
Most of the injectable agents are dosed once weekly, including but not limited to semaglutide (Ozempic/Wegovy), and tirzepatide (Mounjaro/Zepbound).
For the weekly agents, many patients report that appetite suppression (or reduced “food noise”) feels overwhelming in the first day or two after the injection and then negligible in the days leading up to their next dose.
In response, some clinicians have turned to “split dosing” - an off-label practice of dividing the total weekly dose in half and administering the two halves several days apart (often ~3–4 days), with the stated goal of smoothing tolerability and improving sustainability.
A caveat worth putting on the table for discussion is that there is currently no clinical trial evidence validating intra-weekly split dosing for efficacy, tolerability, or safety. The practice is entirely anecdotal and theoretical at this point. The pharmacokinetic rationale is also debatable, depending on the glp1 being used since they each have different half-lives.
This has been quite controversial, and I have colleagues openly for and against it. Would love to hear this group’s thoughts in the comments, particularly anyone with real-world experience or a pharmacologic argument either way.
Educational purposes only. Not medical advice.
